“Impact of the modulator elexacaftor/tezacaftor/ivacaftor (ETI) on the complexity of prescriptions and the clinical stage of children and adolescents with cystic fibrosis”, RSD, vol. 15, no. 1, p. e7715150550, Jan. 2026, doi: 10.33448/rsd-v15i1.50550.